Clinical Trials Show Higher Dosage of Ozempic Boosts Weight Loss

Trials have demonstrated that increasing the dosage of semaglutide, known as Ozempic and Wegovy, can significantly enhance weight loss outcomes. Research published in The Lancet Diabetes & Endocrinology reveals that tripling the dosage from the approved 2.4 mg per week to 7.2 mg resulted in nearly half of the participants shedding 20% or more of their body weight. Approximately one-third experienced a weight loss of at least 25%. The overall average weight loss was recorded at 19%, surpassing the 16% average from the standard dosage and 4% from a placebo group.

Participants in the trials, which were funded by the drug’s manufacturer, Novo Nordisk, received dietary counselling and exercise recommendations alongside their treatments. While these findings highlight the potential for greater weight loss, the authors of the study emphasized that further research is necessary to assess the long-term benefits and risks associated with this higher dosage.

Potential Benefits for Obesity and Diabetes Patients

The increased dosage may provide a promising treatment avenue for individuals struggling with obesity and type 2 diabetes, especially those who have not achieved sufficient weight loss with current therapies. In Ireland, the prevalence of obesity is notable, with approximately one in five people over the age of 15 affected, according to government surveys.

The higher dosage was reported to be generally safe and tolerable. Nevertheless, participants experienced side effects, including nausea, diarrhoea, and dysaesthesia, which manifests as tingling sensations. A small number of individuals required discontinuation of the 7.2 mg regimen due to dysaesthesia, a side effect not observed in those taking the lower dose or the placebo.

Among participants who had both obesity and type 2 diabetes, the average weight loss on the elevated dosage was 13%. This group also showed reductions in blood sugar levels and waist circumference, indicating additional health benefits.

Impact on Novo Nordisk and Market Competition

This new trial data may offer a much-needed boost to Novo Nordisk, particularly as it faces stiff competition from Eli Lilly, which produces the rival weight-loss drug Mounjaro. The Danish pharmaceutical company recently announced plans to cut 9,000 jobs, amounting to an 11% reduction of its workforce, a decision made in light of the fluctuating share prices that have affected the company since last year.

Novo Nordisk communicated that these job cuts would enable the company to streamline operations and redirect resources towards its key growth areas in diabetes and obesity treatment. The ongoing clinical trials and their promising results may play a crucial role in shaping the company’s future as it navigates this competitive landscape.

As Novo Nordisk continues to develop and expand its offerings, the findings from these clinical trials underscore the importance of ongoing research and innovation in addressing the global challenges of obesity and diabetes.